{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Double+Blind&page=43",
    "query": {
      "condition": "Double Blind",
      "page": 43
    },
    "page_size": 10
  },
  "pagination": {
    "page": 43,
    "page_size": 10,
    "total_count": 18300,
    "total_pages": 1830,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Double+Blind&page=44&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Double+Blind&page=42&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T01:51:04.145Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00248040",
      "title": "Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ischemia-Reperfusion Injury",
        "Kidney Diseases"
      ],
      "interventions": [
        {
          "name": "Reparixin continuous infusion",
          "type": "DRUG"
        },
        {
          "name": "reparixin intermittent infusion",
          "type": "DRUG"
        },
        {
          "name": "placebo infusion",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Dompé Farmaceutici S.p.A",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 80,
      "start_date": "2005-10",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2024-01-10",
      "last_synced_at": "2026-11-19T01:51:04.145Z",
      "location_count": 2,
      "location_summary": "Minneapolis, Minnesota • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00248040"
    },
    {
      "nct_id": "NCT04998604",
      "title": "EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Rhinosinusitis With Nasal Polyps",
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Dupilumab",
          "type": "DRUG"
        },
        {
          "name": "Omalizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 360,
      "start_date": "2021-09-27",
      "completion_date": "2024-12-27",
      "has_results": true,
      "last_update_posted_date": "2025-10-23",
      "last_synced_at": "2026-11-19T01:51:04.145Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Tampa, Florida • Chicago, Illinois + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04998604"
    },
    {
      "nct_id": "NCT04516304",
      "title": "A Nutritional Supplement on Vasomotor Symptoms in Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Menopause"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "S-equol",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Pharmavite LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 65 Years · Female only"
      },
      "enrollment_count": 118,
      "start_date": "2019-03-27",
      "completion_date": "2020-05-22",
      "has_results": false,
      "last_update_posted_date": "2024-04-04",
      "last_synced_at": "2026-11-19T01:51:04.145Z",
      "location_count": 1,
      "location_summary": "Addison, Illinois",
      "locations": [
        {
          "city": "Addison",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04516304"
    },
    {
      "nct_id": "NCT03290378",
      "title": "Tramadol Versus Placebo in the Management of Postoperative Pain Following Bunionectomy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pain Management"
      ],
      "interventions": [
        {
          "name": "Tramadol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Avenue Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 409,
      "start_date": "2017-09-19",
      "completion_date": "2018-04-23",
      "has_results": true,
      "last_update_posted_date": "2020-03-19",
      "last_synced_at": "2026-11-19T01:51:04.145Z",
      "location_count": 5,
      "location_summary": "Bakersfield, California • Pasadena, California • Pasadena, Maryland + 2 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "Maryland"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03290378"
    },
    {
      "nct_id": "NCT04684485",
      "title": "To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dermatitis, Atopic"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "SCD-044_Dose 1",
          "type": "DRUG"
        },
        {
          "name": "SCD-044_Dose 2",
          "type": "DRUG"
        },
        {
          "name": "SCD-044_Dose 3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2021-07-30",
      "completion_date": "2025-03-18",
      "has_results": true,
      "last_update_posted_date": "2025-12-30",
      "last_synced_at": "2026-11-19T01:51:04.145Z",
      "location_count": 34,
      "location_summary": "Phoenix, Arizona • Yuma, Arizona • Encino, California + 23 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04684485"
    },
    {
      "nct_id": "NCT00326443",
      "title": "CVD 909 Vi Prime Boost Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Typhoid Fever"
      ],
      "interventions": [
        {
          "name": "CVD 909",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Vi Polysaccharide",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 21,
      "start_date": "2006-02",
      "completion_date": "2008-08",
      "has_results": false,
      "last_update_posted_date": "2014-05-09",
      "last_synced_at": "2026-11-19T01:51:04.145Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00326443"
    },
    {
      "nct_id": "NCT04281108",
      "title": "Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Eosinophilic Esophagitis"
      ],
      "interventions": [
        {
          "name": "APT-1011",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral tablet",
          "type": "DRUG"
        },
        {
          "name": "Esophagogastroduodenoscopy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Ellodi Pharmaceuticals, LP",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 143,
      "start_date": "2020-01-30",
      "completion_date": "2022-10-24",
      "has_results": false,
      "last_update_posted_date": "2023-06-12",
      "last_synced_at": "2026-11-19T01:51:04.145Z",
      "location_count": 48,
      "location_summary": "Anniston, Alabama • Dothan, Alabama • Mobile, Alabama + 43 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04281108"
    },
    {
      "nct_id": "NCT01284517",
      "title": "Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bipolar Depression"
      ],
      "interventions": [
        {
          "name": "Lurasidone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 356,
      "start_date": "2010-11",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2013-11-26",
      "last_synced_at": "2026-11-19T01:51:04.145Z",
      "location_count": 22,
      "location_summary": "Costa Mesa, California • Riverside, California • San Diego, California + 16 more",
      "locations": [
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01284517"
    },
    {
      "nct_id": "NCT07225140",
      "title": "A Study of Combogesic® 325 in Adolescent Patients With Moderate to Severe Postoperative Pain Associated With Orthopedic Surgery",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Post Operative Pain, Acute"
      ],
      "interventions": [
        {
          "name": "Combogesic® tablets",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen 500mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AFT Pharmaceuticals, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 180,
      "start_date": "2026-10",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-11-19T01:51:04.145Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07225140"
    },
    {
      "nct_id": "NCT02473289",
      "title": "An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Depressive Disorder, Major"
      ],
      "interventions": [
        {
          "name": "Sirukumab 50 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "21 Years to 64 Years"
      },
      "enrollment_count": 193,
      "start_date": "2015-07-23",
      "completion_date": "2018-05-22",
      "has_results": true,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-11-19T01:51:04.145Z",
      "location_count": 24,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Bellflower, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Lemon Grove",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02473289"
    }
  ]
}